התחל במצב לא מקוון עם האפליקציה Player FM !
פודקאסטים ששווה להאזין
בחסות
1 Patti Truant Anderson: Polling and the Surprising Results Around What People Really Think About the Food System 24:55
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
Manage episode 447191630 series 3389426
touchCONGRESS for touchONCOLOGY
Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.
Overview
- Data reviews with Prof. Rosti
- Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below
Clinical themes
- Approved and emerging TKIs for CML in the first-line setting
- Approved and emerging TKIs for CML in the second- and later-line settings
- Potential impact of emerging data on current and future clinical practice
The internationally renowned multiple myeloma expert faculty
- Prof. Gianantonio Rosti: Meldola, Italy
- Prof. Susanne Saussele: Mannheim, Germany
- Dr Carla Boquimpani: Rio de Janeiro, Brazil
This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.
This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: TBC
102 פרקים
Manage episode 447191630 series 3389426
touchCONGRESS for touchONCOLOGY
Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.
Overview
- Data reviews with Prof. Rosti
- Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below
Clinical themes
- Approved and emerging TKIs for CML in the first-line setting
- Approved and emerging TKIs for CML in the second- and later-line settings
- Potential impact of emerging data on current and future clinical practice
The internationally renowned multiple myeloma expert faculty
- Prof. Gianantonio Rosti: Meldola, Italy
- Prof. Susanne Saussele: Mannheim, Germany
- Dr Carla Boquimpani: Rio de Janeiro, Brazil
This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.
This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: TBC
102 פרקים
כל הפרקים
×1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37
1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38
1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15
1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20
1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19
1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58
1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46
1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05
1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14
1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57
ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.